Supplement

You have full text access to this OnlineOpen article

Preventing cervical cancer †‡

Overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs

  1. Kris Khan MS, RN1,§,*,
  2. C. Robinette Curtis MD, MPH2,
  3. Donatus U. Ekwueme PhD1,
  4. Shannon Stokley MPH2,
  5. Chastity Walker MPH1,
  6. Katherine Roland MPH1,
  7. Vicki Benard PhD1,
  8. Mona Saraiya MD, MPH1

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23765

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 3004–3012, 15 November 2008

Additional Information

How to Cite

Khan, K., Curtis, C. R., Ekwueme, D. U., Stokley, S., Walker, C., Roland, K., Benard, V. and Saraiya, M. (2008), Preventing cervical cancer . Cancer, 113: 3004–3012. doi: 10.1002/cncr.23765

Author Information

  1. 1

    Centers for Disease Control and Prevention, National Center for Chronic Disease and Health Promotion, Division of Cancer Prevention and Control, Atlanta, Georgia

  2. 2

    Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division, Atlanta, Georgia

  1. §

    Fax: (770) 488-3230.

*Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Program Services Branch, 4770 Buford Highway, MS K-57, Chamblee, GA 30341;

  1. †

    The opinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the journal editors, the American Cancer Society, Wiley-Blackwell, or the Centers for Disease Control and Prevention.We are very grateful to Ms. Sharon A. Bisner and colleagues for allowing us to include information about the New York State Department of Health Cancer Services Program in this article. We also thank Ms. Nancy Fasano and Dr. Greg Wallace for their helpful reviews of the article

  2. ‡

    This is a US government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 2 JUN 2008
  4. Manuscript Received: 25 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention (CDC)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (131K)

REFERENCES

  • 1
    Munoz N,Bosch FX,De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518–527.
  • 2
    Wheeler CM. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol. 2007; 4: 224–235.
  • 3
    Huh WK, and the Quadrivalent HPV Vaccine Phase IIb/IIIb Investigator. Impact of quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle vaccine on the incidence of abnormal pap tests and cervical procedures [abstract]. Gynecol Oncol. 2008; 108( suppl 1): s11. Abstract presented at Annual Meeting of Society of Gynecology Oncologists, March 9, 2008, Tampa, Florida.
  • 4
    Singh GK,Miller BA,Hankey BF,Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004; 101: 1051–107.
    Direct Link:
  • 5
    U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2005.
  • 6
    Adams SH,Newacheck PW,Park JM,Brindis CD,Irwin CE. Health insurance across vulnerable ages: Patterns and disparities from adolescence to the early 30s. Pediatrics. 2007; 119: e1033–e1039.
  • 7
    Cohen RA,Martinez ME. Health insurance coverage: early release of estimates from the National Health Interview Survey. Clin Exp Obstet Gyn. 2006;(document posted 2007 June 25, website updated 2007 July 9, cited 2007 July 12). Available at: http://www.cdc.gov/nchs/nhis.htm Accessed July 12, 2007.
  • 8
    Dubard CA,Massing MW. Trends in emergency Medicaid expenditures for recent and undocumented immigrants. JAMA. 2007; 297: 1085–1092.
  • 9
    Markowitz LE,Dunne EF,Saraiya M,Lawson HW,Chesson H,Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2007; 56(RR-2): 1–24.
  • 10
    Public Law 101-354. Title 42. The Public Health and Welfare. Chapter 6a, The Public Health Service. Preventive Health Measures with Respect to Breast and Cervical Cancers 42. U.S.C. § 300k, US Congress 1990.
  • 11
    Centers for Disease Control and Prevention. National Breast and Cervical Cancer Early Detection Program. Page last updated: February 25, 2008. Available at: http://www.cdc.gov/cancer/nbccedp/about.htm Accessed on July 29, 2008.
  • 12
    Saraiya M,Irwin KL,Carlin L, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer. 2007; 110: 1024–1032.
    Direct Link:
  • 13
    Swan J,Breen N,Coates R,Rimer B,Lee N. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 1528–1540.
    Direct Link:
  • 14
    Benard V,Coughlin SS,Thompson T,Richardson LC. Cervical cancer incidence in the United States by area of residence, 1998-2001. Obstet Gynecol. 2007; 110: 681–686.
  • 15
    McDougall J,Madeleine MM,Daling JR,Li C. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control. 2007; 18: 1175–1186.
  • 16
    Saraiya M,Ahmed F,King J, et al. Cervical cancer incidence in a pre-vaccine era—United States, 1998-2002. Obstet Gynecol. 2007; 109: 360–370.
  • 17
    Centers for Disease Control and Prevention. Recruitment. The National Breast and Cervical Cancer Early Detection Program Manual. Atlanta, Georgia: US Department of Health and Human Services; 2007.
  • 18
    Centers for Disease Control and Prevention. Report to Congress on 317 Immunization Program. Atlanta, Georgia: US Department of Health and Human Services; 2007.
  • 19
    Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years—United States, 2008. MMWR. 2008; 57: Q1–Q4.
  • 20
    Centers for Disease Control and Prevention. Recommended adult immunization schedule—United States, October 2007-September 2008. MMWR. 2007; 56: Q1–Q4.
  • 21
    Centers for Disease Control and Prevention. Vaccine Management Business Improvement Project; (document dated 2007 February, website updated 2007 April 9, cited 2007 October 4). Available at: http://www.cdc.gov/vaccines/about/pibs/downloads/vmbip.pdf Accessed October 4, 2007.
  • 22
    Orenstein WA,Mootrey GT,Pazol K,Hinman AR. Financing immunization of adults in the United States. Clin Pharmacol Ther. 2007; 82: 764–768.
  • 23
    Santoli J,Rodewald L,Maes E,Battaglia M,Coronado V. Vaccines for Children Program, United States, 1997. Pediatrics. 1999; 104: e15.
  • 24
    Orenstein WA. The role of measles elimination in development of a national immunization program. Pediatr Infect Dis J. 2006; 25: 1093–1101.
  • 25
    Centers for Disease Control and Prevention. Which children are eligible for the VFC Program? 2008. Available at: http://www.cdc.gov/vaccines/programs/elig-scrn-rec.doc-req.htm Accessed on July 29, 2008.
  • 26
    Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2005; 54(RR-7): 1–21.
  • 27
    Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006; 55(RR-3): 1–43.
  • 28
    Centers for Disease Control and Prevention. Adolescent immunization. In: 2008-2012 Immunization Program Operations Manual (document posted 2007 April 10, website updated 2007 October 2, cited 2008 February 1). Available at: http://www.cdc.gov/vaccines/vac-gen/policies/ipom/downloads/chp-06-adolescent-iz.pdf
  • 29
    Centers for Disease Control and Prevention. Notice to Readers: revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR. 2007; 56: 794–795.
  • 30
    Orenstein WA. Testimony on the immunization grant program of the PHS Act, 1997. Available at: http://www.hhs.gov/asl/testify/t970506a.html. Accessed archive page April 25, 2008.
  • 31
    Centers for Disease Control and Prevention. CDC vaccine price list; 2008. Available at: http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm (updated 2008 February 5). Accessed February 20, 2008.
  • 32
    Roush SW,Murphy TV, and the Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007; 298: 2155–2163.
  • 33
    Wooten KG,Darling N,Singleton JA,Shefer A. National, state, and local area vaccination coverage among children aged 19-35 months—United States, 2006. MMWR. 2007; 56: 880–885.
  • 34
    Rein DB,Honeycutt AA,Rojas-Smith L,Hersey JC. Impact of the CDC's Section 317 Immunization Grants Program Funding on childhood vaccination coverage. Am J Public Health. 2006; 96: 1548–1553.
  • 35
    Castle PE,Solomon D,Saslow D,Schiffman M. Commentary. Predicting the effect of successful HPV vaccination on existing US cervical cancer prevention programs. Cancer. 2008; 113(10 suppl): 3031–3035.
    Direct Link:
  • 36
    Dasbach EJ,Elbasha EH,Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006; 28: 88–100.
  • 37
    Goldie SJ,Kohli M,Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604–615.
  • 38
    Kulasingam SL,Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781–789.
  • 39
    Taira AV,Neukerman CP,Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2007; 10: 1915–1923.
  • 40
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007; 111: 145–153.
    Direct Link:
  • 41
    Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med. 2006; 354: 1109–1112.
  • 42
    Sanders GD. Cost effectiveness of a potential vaccine forhuman papillomavirus. Emerg Infect Dis. 2003; 9: 37–48.
  • 43
    Follen M,Richards-Kortum R. Emerging technologies and cervical cancer. J Natl Cancer Inst. 2000; 92: 363–365.
  • 44
    Insinga RP,Dasbach EJ,Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005; 23: 1107–1122.
  • 45
    Schiller JT. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol. 2004; 2: 343–347.
  • 46
    Benard VB,Eheman CR,Lawson HW, et al. Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001. Obstet Gynecol. 2004; 103: 564–571.
  • 47
    Benard VB,Lawson HW,Eheman CR,Anderson C,Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005; 105: 1323–138.
  • 48
    Centers for Disease Control and Prevention (CDC). The National Breast and Cervical Cancer Early Detection Program: 1991-2002 National Report. Atlanta, Georgia: Department of Health and Human Services; 2005.
  • 49
    Winer RL,Lee S-K,Hughes JP,Adam DE,Kiviat NB,Koutsky LA. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157: 218–226.
  • 50
    Dunne EF,Unger ER,Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813–819.
  • 51
    Newall AT,Beutels P,Wood JG,Edmunds WJ,MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis. 2007; 7: 289–296.
  • 52
    Ekwueme DU,Gardner JG,Subramanian S,Tangka FK,Bapat B,Richardson LC. Cost analysis of the National Breast and Cervical Cancer Early Detection Program—selected states. Cancer. 2008; 112: 626–635.
    Direct Link:
  • 53
    Helms LJ,Melnikow J. Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Med Care. 1999; 37: 652–661.
  • 54
    Myers ER,Mccrory DC,Subramanian S,Mccal N,Nanda K, et al. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. Obstet Gynecol. 2000; 96: 645–652.
  • 55
    Kulasingam SL,Kim JJ,Lawrence WF, et al. Cost effectiveness analysis based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2006; 98: 92–100.
  • 56
    US Bureau of Labor and Statistics. Consumer price indexes: Bureau of Labor and Statistics, 2003. Washington, DC: US Bureau of Labor and Statistics; 2003. Available at: http://www.bls.gov/cpi/ Accessed August 27, 2007.
View Full Article (HTML) Get PDF (131K)